INTRODUCTION: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. METHODS: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. RESULTS: Of the 586 consecutive patients studied, there were 232 (39.6%) with BMI <25, 232 (39.6%) with BMI 25 to <30, 89 (15.2%) with BMI 30 to <35, and 33 (5.6%) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P= 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. CONCLUSIONS: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.
INTRODUCTION: The obesity epidemic coupled with epidemiologic evidence of the link between pancreatic cancer and obesity has raised the interest in the impact of body mass index (BMI) on outcomes for resected pancreatic cancer. METHODS: All patients who underwent pancreatoduodenectomy (PD) for pancreatic adenocarcinoma from 1981 to 2007 were categorized into four groups according to their BMI (<25, 25 to <30, 30 to <35, and ≥35). Associations of these BMI groups with perioperative (operating time, blood loss, complications, in-hospital mortality), pathologic (tumor diameter, tumor stage, differentiation, lymph node status, R0 status) features and long-term patient outcome were evaluated using Kruskal-Wallis and chi-square tests, logistic regression, and Cox proportional hazards regression. A second set of analyses were performed by dichotomizing patients into morbidly obese (BMI ≥ 35) in comparison to the rest. RESULTS: Of the 586 consecutive patients studied, there were 232 (39.6%) with BMI <25, 232 (39.6%) with BMI 25 to <30, 89 (15.2%) with BMI 30 to <35, and 33 (5.6%) with BMI ≥ 35. Operating time (P = 0.003) and intraoperative blood loss (P < 0.001) increased with BMI, although none of the remaining perioperative features differed significantly among the BMI groups. Similarly, there were no significant associations between BMI group and the pathological features studied, particularly lymph node status (P= 0.98). BMI was not associated with lymph node status even after adjusting for tumor diameter. All analyses were repeated for the morbidly obese. Cox regression did not demonstrate an impact of BMI or morbid obesity on overall or disease-free survival. CONCLUSIONS: BMI (and morbid obesity) does not appear to influence long-term outcomes for patients undergoing PD. Surgeons should be vigilant of the greater risk of perioperative blood loss with increasing BMI.
Authors: Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari Journal: Am J Gastroenterol Date: 2009-06-09 Impact factor: 10.864
Authors: O Fathy; M Abdel M Wahab; N Elghwalby; A Sultan; G EL-Ebidy; N GadEl Hak; M Abu Zeid; T Abd-Allah; M El-Shobary; A Fouad; Th Kandeel; A Abo Elenien; A Abd El-Raouf; E Hamdy; A M Sultan; E Hamdy; Farouk Ezzat Journal: Hepatogastroenterology Date: 2008 May-Jun
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2007-10-26 Impact factor: 22.682
Authors: Michael G House; Yuman Fong; Dean J Arnaoutakis; Rohit Sharma; Corinne B Winston; Mladjan Protic; Mithat Gonen; Sara H Olson; Robert C Kurtz; Murray F Brennan; Peter J Allen Journal: J Gastrointest Surg Date: 2007-12-01 Impact factor: 3.452
Authors: Timothy K Williams; Ernest L Rosato; Eugene P Kennedy; Karen A Chojnacki; Jocelyn Andrel; Terry Hyslop; Cataldo Doria; Patricia K Sauter; Jordan Bloom; Charles J Yeo; Adam C Berger Journal: J Am Coll Surg Date: 2008-12-18 Impact factor: 6.113
Authors: Matthew Benns; Charles Woodall; Charles Scoggins; Kelly McMasters; Robert Martin Journal: Ann Surg Oncol Date: 2009-06-26 Impact factor: 5.344
Authors: Marianne Huebner; Michael Kendrick; Kaye M Reid-Lombardo; Florencia Que; Terry Therneau; Rui Qin; John Donohue; David Nagorney; Michael Farnell; Michael Sarr Journal: J Gastrointest Surg Date: 2012-03-16 Impact factor: 3.452
Authors: Chen Yuan; Ying Bao; Chen Wu; Peter Kraft; Shuji Ogino; Kimmie Ng; Zhi Rong Qian; Douglas A Rubinson; Meir J Stampfer; Edward L Giovannucci; Brian M Wolpin Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544